SP-103

Scilex Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	SP-103
Sponsor	Scilex Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain (PHASE2)
OCR002-SP103 - Oral Immediate Release Study (PHASE1)
Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SP-103 CI brief — competitive landscape report
SP-103 updates RSS · CI watch RSS
Scilex Pharmaceuticals, Inc. portfolio CI